BURLINGTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) – LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices, implants and services, today announced the price of a subscribed public offering of 1,000,000 common shares at a public offering price of $ 54.50 per action. The gross proceeds of the Offering for LeMaitre are expected to be approximately $ 54.5 million before the deduction of any sales rebates and commissions and the estimated offering fees payable by LeMaitre. The offer is expected to close on or around July 16, 2021, subject to customary closing conditions. LeMaitre has granted the underwriters of the offer the right for a period of 30 days to purchase up to 150,000 additional common shares at the public offer price, less underwriting discounts and commissions.
Jefferies and Stifel are acting as co-book managers for the proposed offering. KeyBanc Capital Markets acts as lead co-manager, and Barrington Research, Lake Street Capital Markets, LLC and Sidoti & Company, LLC act as co-managers.
LeMaitre intends to use the net proceeds of the Offering to repay all outstanding borrowings under its senior secured credit facility and for general corporate purposes, including working capital and expenses. in capital and payments under its quarterly dividend program. LeMaitre may also use a portion of the net proceeds to finance possible future acquisitions.
A registration statement relating to these securities has been filed with the United States Securities and Exchange Commission (SEC) and became effective June 1, 2020. The offer is being made only by means of a written prospectus and a prospectus supplement which forms part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been previously filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the Final Prospectus Supplement and the accompanying prospectus relating to the Offer can be obtained, when available, by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by email at prospectus_department @ jefferies.com, or by phone at (877) 821-7388; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by phone at 415-364-2720 or by email at [email protected]
This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal, before registration or qualification. under the securities laws of any such state or jurisdiction.
LeMaitre is a supplier of devices for the treatment of peripheral vascular disease, a disease that affects more than 200 million people worldwide. LeMaitre develops, manufactures and markets disposable and implantable vascular devices to meet the needs of its primary customer, the vascular surgeon.
To the extent that the statements contained in this press release are not descriptions of historical fact concerning LeMaitre, they are forward-looking statements reflecting the current beliefs and expectations of management made in accordance with the safe harbor of the Private Securities Litigation Reform Act. 1995, including LeMaitre’s intended use of the proceeds of the proposed public offering. Such forward-looking statements involve substantial risks and uncertainties which could cause LeMaitre’s future results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, uncertainties related to market conditions and the completion of the public offer on the terms expected or not at all. LeMaitre does not undertake to update or revise any forward-looking statements. For a more detailed description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as the risks associated with LeMaitre’s business in general, please refer to the LeMaitre prospectus supplement to be filed. with the SEC, including documents incorporated by reference therein, which include LeMaitre’s Annual Report on Form 10-K filed with the SEC on March 12, 2021, LeMaitre’s Quarterly Report on Form 10-Q filed with of the SEC on May 10, 2021, and LeMaitre’s other periodic reports filed with the SEC.